Myopia Treatment

Dr. Labiento Smith controls early myopia progression with low-dose Atropine and/or Orthokeratology. She bases her treatment on the current literature and recent LAMP study. These treatments for myopia control are considered an off-label use in the United States..  The medication Atropine and Ortho-K are FDA approved but under a different category and use. All children with active myopia progression at Sudbury Eye Care are seen bi-annually for exams to monitor progression.